Disclosures for "Individualized Antisense Oligonucleotides for SCN2A Related Developmental Epileptic Encephalopathy"
-
Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biomarin. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biomarin. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis Precision Medicines. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Illumina. Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Illumina . Dr. Kim Mcmanus has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Kim Mcmanus has received research support from California Institute for Regenerative Medicine. The institution of Dr. Kim Mcmanus has received research support from National Institutes of Health/NCATS.
-
Dr. Mignon has received personal compensation for serving as an employee of n-Lorem Foundation. Dr. Mignon has stock in Ionis Pharmaceuticals, JNJ, Nvidia.. The institution of Dr. Mignon has received research support from CIRM.
-
Dr. douville has nothing to disclose.
-
Dr. Pu has received personal compensation for serving as an employee of n-Lorem Foundation.
-
Ms. Parisien has nothing to disclose.
-
Dr. Glass has received personal compensation for serving as an employee of n-Lorem Foundation .
-
Author has nothing to disclose
-
Mrs. Celso has nothing to disclose.
-
Ms. Robbins has nothing to disclose.
-
Mrs. Protopsaltis has nothing to disclose.
-
Stephen Kingsmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Third Rock Ventures. Stephen Kingsmore has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB2 Bio. Stephen Kingsmore has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Illumina. Stephen Kingsmore has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ACMGG. Stephen Kingsmore has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Stephen Kingsmore has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Rady Children's Institute for Genomic Medicine. Stephen Kingsmore has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Sidra Medicine. Stephen Kingsmore has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Stephen Kingsmore has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cold Spring Harbor Press. Stephen Kingsmore has stock in Third Rock Ventures. The institution of Stephen Kingsmore has received research support from Alexion, Amgen, Biomarin, Chiesi, Inozyme, Ionis, Mahzi, Orchard, Sanofi, Rocket, Sarepta, Sentynyl, Travere, Ultragenyx. The institution of Stephen Kingsmore has received research support from NIH. Stephen Kingsmore has received intellectual property interests from a discovery or technology relating to health care. Stephen Kingsmore has received intellectual property interests from a discovery or technology relating to health care.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Prof. Gleeson has received personal compensation for serving as an employee of Ionis. Prof. Gleeson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine.
-
The institution of Dr. Berry-Kravis has received research support from NIH. The institution of Dr. Berry-Kravis has received research support from Ionis. The institution of Dr. Berry-Kravis has received research support from Zynerba. The institution of Dr. Berry-Kravis has received research support from Roche. The institution of Dr. Berry-Kravis has received research support from CDC. The institution of Dr. Berry-Kravis has received research support from FRAXA Research Foundation. The institution of Dr. Berry-Kravis has received research support from GeneTx. The institution of Dr. Berry-Kravis has received research support from Angelman Syndrome Foundation. The institution of Dr. Berry-Kravis has received research support from Acadia. The institution of Dr. Berry-Kravis has received research support from Ultragenyx. The institution of Dr. Berry-Kravis has received research support from Mallinckrodt. The institution of Dr. Berry-Kravis has received research support from Together Strong Foundation. The institution of Dr. Berry-Kravis has received research support from Zevra. The institution of Dr. Berry-Kravis has received research support from Taysha. The institution of Dr. Berry-Kravis has received research support from Tetra. The institution of Dr. Berry-Kravis has received research support from Neuren.